The New England Journal of Medicine has reported the results of a large clinical trial demonstrating the efficacy of ustekinumab (Stelara) in treating patients with active Crohn's disease (CD). (Citation source http://buff.ly/2gsSNcs)
It is well known that ANCA-associated vasculitides can be hard to control and relapses are common. The choice of maintenance therapy is rather limited and therapies are not always effective.In the past, the randomized controlled prospective MAINRISTAN trial demonstrated superiority of rituxan (RTX) over azathioprine for maintenance of remission at 22 months in patients with ANCA-associated vasculitis after CYC remission induction.
The offspring of women with rheumatoid arthritis (RA) may be at greater risk for the development of epilepsy, according to a recent report in the journal Neurology, suggesting that epileptogenic triggers may begin during pregnancy and may be worsened by RA flares or the treatment for RA. (Citation source: http://buff.ly/2g4QgSD)
Dr. Philip Mease, MD presented the long-term efficacy and safety data for secukinumab in psoriatic arthritis (PsA) at the ACR Annual meeting in Washington, DC. (abstract 961)
Washington is always a great city to visit (even though there were a few protesters floating around the streets). I hope the posts I made were of interest to some readers. Here are my top 5 highlights from ACR 2016:
Dr. Jack Cush: Summarizing ACR 2016
Dr. Jack Cush summarizes the 2016 ACR/ARHP Annual Meeting, highlighting in Abstract 89 (Workforce Study), Abstract 19L (Nor Switch study), and Abstract 3006 (macrophage activation syndrome).
The final day of the 2016 annual ACR meeting saw the return of "Rheumatology Round-up" at 7:30am in Hall D.Drs. Jack Cush and Artie Kavanaugh started with announcing that this was the 80th annual scientific session for the ACR and that this meeting had over 17,000 attendees, nearly 3250 abstracts and over 200 sessions.
Dr. Jack Cush: RWCS 2017 Conference
Dr. Jack Cush previews the RWCS 2017 meeting in Maui. Registration is now open.
The notion of a single biologic targeting two cytokines is intriguing. ABT-122 is a new dual-variable domain immunoglobulin that neutralizes both TNF-α and IL-17A.
Dr. Olga Petryna: Role of TNFi on anti-Lymphoma Activity
Dr. Olga Petryna discusses a French study that looks at the role of TNF inhibitors on anti-lymphoma activity.
All week I’ve attempted to catch the spirit of ACR and rheumatology in a picture or quote, but after attending ACR 2016 in Washington, DC, I found myself surrounded by examples.
Some big highlights from Tuesday at the 2016 ACR/ARHP annual meeting included the PRECISION trial, EXXELERATE trial and the new anti-IL-23 in psoriatic arthritis.
